Physician profile
Timothy E Ballard
NPI 1053411355
$46,670.59
in general payments reported to CMS, 2019-2025
40 companies · $3,099 in 2025
The $3,099 reported for 2025 was more than what 98% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,143 · 2022: $17K · 2023: $17K · 2024: $8,320 · 2025: $3,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $11K · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,250.00 |
| Food and Beverage | $10,570.61 |
| Education | $105.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $33,497.20 | 2021-2025 | Lifevest |
| Amgen INC. | $1,904.02 | 2021-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $1,734.16 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $832.33 | 2021-2025 | Uptravi, Opsumit |
| Astrazeneca Pharmaceuticals LP | $762.18 | 2021-2025 | Farxiga, Wainua |
| Pfizer INC. | $642.48 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $609.83 | 2021-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $523.84 | 2021-2025 | Camzyos, Eliquis |
| Cvrx, INC. | $514.98 | 2023-2025 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $467.20 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $437.31 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $403.83 | 2021-2024 | Ultreon, Mini Trek, Aveir |
| Bayer Healthcare Pharmaceuticals INC. | $398.37 | 2022-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $381.76 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $379.58 | 2021-2025 | Verquvo |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $365.65 | 2023-2025 | Ffrct |
| Atricure, INC. | $353.29 | 2024 | |
| Scpharmaceuticals INC. | $295.25 | 2024-2025 | |
| Amarin Pharma, INC. | $282.21 | 2021-2023 | |
| Boston Scientific Corporation | $277.00 | 2021-2025 | Watchman Flx, Spaceoar Vue System - 10ml, Bodyguardian |
| Philips North America LLC | $254.56 | 2022-2024 | (Ck4) Mcot |
| Esperion Therapeutics, INC. | $236.95 | 2021-2025 | Nexletol |
| Baxter Healthcare | $157.31 | 2023 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Medtronic, INC. | $142.49 | 2021-2023 | Hawkone |
| Inari Medical, INC. | $130.71 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Daiichi Sankyo INC. | $118.20 | 2021-2023 | Injectafer |
| Silk Road Medical, INC. | $97.82 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Regeneron Healthcare Solutions, INC. | $88.55 | 2021-2023 | Evkeeza |
| Edwards Lifesciences Corporation | $68.07 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $66.07 | 2023-2024 | |
| Preventice Services, LLC | $47.75 | 2021 | |
| Bridgebio Pharma, INC. | $47.40 | 2025 | Attruby |
| Kiniksa Pharmaceuticals, LTD. | $37.39 | 2023 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $26.55 | 2025 | Amvuttra |
| Medicomp INC | $20.84 | 2022 | |
| Vivaquant INC, Dba Rhythm Express | $15.40 | 2025 | Rhythm Express |
| Amryt Pharma Holdings LTD | $14.20 | 2021 | |
| Elutia, INC. | $13.49 | 2022 | |
| Azurity Pharmaceuticals, INC. | $12.80 | 2023 | Edarbi |
| Kowa Pharmaceuticals America, INC. | $11.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Ballard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.